Brought to you by:
Beyond the procedure: Rethinking long-term AVF success with VasQ
This advertorial is sponsored by Laminate Medical. What happens after a fistula is created can be just as important as the procedure itself. Dion Franga, MD, shares how innovations like VasQ may help improve fistula maturation, reduce catheter time and…
Advancing dialysis access outcomes with extravascular support: A triangulated clinical research approach
This advertorial is sponsored by Laminate Medical. Arteriovenous fistula (AVF) creation remains one of the most frequent, yet frustrating procedures performed by vascular surgeons. While AVFs stand as a cornerstone of care for end-stage kidney disease (ESKD) patients, the reality…
Acellular tissue engineered vessel outperforms AVF in high-risk hemodialysis patients
Results from the CLN-PRO-V007 randomized controlled trial of Humacyte’s acellular tissue engineered vessel (ATEV) are set to be shared today during VAM 2025 Plenary 6 (10–11 a.m., First Floor, Great Hall A), showing several clinical benefits when compared to arteriovenous…
Novel bioabsorbable perivascular wrap aims to reduce AVF failure
Ellen Dillavou, MD, division chief of vascular surgery at WakeMed Heart Center in Raleigh, North Carolina, primary investigator (PI) for the VenoStent trial, presented new data during the 2024 VEITHsymposium in New York City (Nov. 19–23) about the SelfWrap (VenoStent)…
WAVE trial AVG cohort also benefits at six months with Wrapsody
Newly released six-month results from single-arm arteriovenous graft (AVG) cohort in the WAVE (Wrapsody arteriovenous access efficacy) trial showed target lesion and access circuit primary patency rates of nearly 82% and 68.8%, respectively. The latest data on the Wrapsody cell-permeable…
VasQ: The next standard-of-care innovation
This advertorial is sponsored by Laminate Medical Technologies. At the 2024 Charing Cross (CX) International Symposium (April 23–25) in London, England, the Vascular Access Masterclass Controversies session delved into the question, “We have new technology, but do we need it?”…
Vascular external support system use found to boost key functional outcomes for surgical arteriovenous fistula creation
Alik Farber, MD, professor of surgery and radiology at Boston University, is set to present the results of a multicenter U.S. study at the 2024 Society for Clinical Vascular Surgery (SCVS) annual meeting (March 16–20) in Scottsdale, Arizona, that will…
VasQ AVF creation device receives FDA clearance
Laminate Medical Technologies has announced their flagship device, the VasQ external vascular support, has been cleared by the Food and Drug Administration (FDA) for use to create arteriovenous fistulas (AVFs) for dialysis access. The device, designated by the FDA as…
Light-activated drug-coated balloon granted FDA approval for clinical study
Alucent Biomedical has announced that the Food and Drug Administration (FDA) granted an investigational device exemption (IDE) for a U.S. clinical study of AlucentNVS, a light-activated, drug-coated balloon catheter technology. AlucentNVS combines an intravascular device with a photochemical process to…
Amplifi vein dilation system continues to show promise following latest first-in-human study update
An update from the first-in-human study assessing the Amplifi vein dilation system (Artio Medical) was delivered by Surendra Shenoy, MD, from Washington University School of Medicine in St Louis, during the first-ever late-breaking clinical trials session at this year’s Venous Endovascular…